“If we can detect infections early, we can optimize antimicrobial treatment and prevent transmission within our healthcare system. The BD MAX allows us to do that.”

Professor, Nagasaki University

Expand your lab’s molecular testing potential

- **Workflow efficiency** for timely patient management
- **Diagnostic speed and accuracy** to aid in fast, appropriate treatment
- **Testing versatility** for a wide range of patients

Visit [moleculardiagnostics.bd.com](http://moleculardiagnostics.bd.com) to find out how
Why BD?

The BD MAX™ System delivers automated extraction, amplification, and detection of the most common HAIs, with up to 24 patient results in just over 2 hours.

Why change?

BD MAX™ MRSA XT:
A screening test for nasal carriage of MRSA aiding in transmission prevention and infection control. The assay provides comprehensive coverage of 11 sequences of the SCCmec-orfX right-extremity junction (MREJ) region plus identification of mecA drop-out mutants and detection of the newly emerging mecC gene.

BD MAX™ StaphSR:
A pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA to aid in transmission prevention and infection control. The assay offers the same level of comprehensive coverage as the BD MAX MRSA XT assay, including detection of the 11 MREJ regions, mecA drop-out mutants and the newly emerging mecC gene.

BD MAX™ Cdiff:
A test for patients suspected of having Clostridium difficile infection (CDI) through the detection of the C difficile toxin B gene (tcdB) from liquid or soft stool. The assay provides a highly accurate result in an actionable timeframe and requires limited hands-on time as compared to traditional methods.

Why now?

Because when early and accurate detection of HAIs is combined with appropriate infection control interventions and patient treatment, we can support antimicrobial stewardship initiatives, prevent transmission, and improve patient management to reduce the financial burden on healthcare systems.

The BD MAX System is a single platform capable of running BD and partner developed assays, as well as laboratory-developed tests (LDTs).

Women’s Health and STIs
- CT/GC/TV
- GBS
- Vaginal Panel

Enteric Solutions
- Enteric Bacterial Panel
- Enteric Parasite Panel
- Extended Enteric Bacterial Panel

Open-System Reagents
- DNA or TNA Extraction
- DNA or TNA Amplification

References:

Why BD?

The BD MAX™ System delivers automated extraction, amplification, and detection of the most common HAIs, with up to 24 patient results in just over 2 hours.

Why change?

BD MAX™ MRSA XT:
A screening test for nasal carriage of MRSA aiding in transmission prevention and infection control. The assay provides comprehensive coverage of 11 sequences of the SCCmec-orfX right-extremity junction (MREJ) region plus identification of mecA drop-out mutants and detection of the newly emerging mecC gene.

BD MAX™ StaphSR:
A pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA to aid in transmission prevention and infection control. The assay offers the same level of comprehensive coverage as the BD MAX MRSA XT assay, including detection of the 11 MREJ regions, mecA drop-out mutants and the newly emerging mecC gene.

BD MAX™ Cdiff:
A test for patients suspected of having Clostridium difficile infection (CDI) through the detection of the C difficile toxin B gene (tcdB) from liquid or soft stool. The assay provides a highly accurate result in an actionable timeframe and requires limited hands-on time as compared to traditional methods.

Why now?

Because when early and accurate detection of HAIs is combined with appropriate infection control interventions and patient treatment, we can support antimicrobial stewardship initiatives, prevent transmission, and improve patient management to reduce the financial burden on healthcare systems.

The BD MAX System is a single platform capable of running BD and partner developed assays, as well as laboratory-developed tests (LDTs).

Women’s Health and STIs
- CT/GC/TV
- GBS
- Vaginal Panel

Enteric Solutions
- Enteric Bacterial Panel
- Enteric Parasite Panel
- Extended Enteric Bacterial Panel

Open-System Reagents
- DNA or TNA Extraction
- DNA or TNA Amplification

References:

Setting higher standards in the fight against HAIs

Why change?

~55,000 patients contracted an MRSA infection while hospitalized

Patients with an MRSA surgical site infection have up to 11 times higher rate of mortality

~15,000 patient deaths from CDI

Why now?

Because when early and accurate detection of HAIs is combined with appropriate infection control interventions and patient treatment, we can support antimicrobial stewardship initiatives, prevent transmission, and improve patient management to reduce the financial burden on healthcare systems.

The BD MAX System is a single platform capable of running BD and partner developed assays, as well as laboratory-developed tests (LDTs).

References:

Start maximizing your impact

Contact your Local Representative

BD, Sparks, MD 21152-0999 USA
800.638.8663

bd.com

© 2018 BD. BD, the BD Logo and BD MAX are trademarks of Becton, Dickinson and Company.